About
Technology
Issues
FAQ
Links
Official Page
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.